Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTOME study
ISRCTN66216819Phase 3Completed
- Sponsor
- King's College Hospital
- Start
- Jun 2011
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
01
Overview
Phase 3, open-label, single-arm trial of ozurdex in macular edema, sponsored by King's College Hospital. Primary endpoint: Mean change in OCT at 4-weekly time points. Started Jun 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
macular edema
Beyond the preview
Go deeper on ISRCTN66216819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66216819.